Basilea Pharmaceutica - 2020 vision on derazantinib in iCCA
Basilea Pharmaceutica is a revenue-generating biotech company that is on the cusp of breaking even (2021e) and sustainable profitability...
996 Views
Basilea Pharmaceutica - Strength in numbers
Basilea reported a definable FY17, as a multitude of licensing/distribution agreements announced in 2016/17 for launched anti-infective drug assets...
68 Views
Basilea Pharmaceutica - Pfizer Cresemba deal extended to Asia and China
Basilea has announced an extension to its licence agreement with Pfizer (PFE) for Cresemba (for invasive fungal infections). The original deal...
69 Views
The future looks bright
Basilea’s prognosis looks good. Multiple licensing/distribution agreements announced for launched assets Cresemba and Zevtera should drive top-line...
53 Views
Hat trick
Basilea announced a hat trick of positive news flow in June. This includes two separate licensing deals covering Cresemba (for invasive mould...
66 Views